Progressive sleep “destructuring” in Parkinson’s disease. A polysomnographic study in 46 patients. Sleep Med 6:313-318

Department of Neuroscience, Centre Hospitalier de Luxembourg, 4, rue Barblé, L-1210 Luxembourg, Luxembourg.
Sleep Medicine (Impact Factor: 3.15). 08/2005; 6(4):313-8. DOI: 10.1016/j.sleep.2005.03.011
Source: PubMed


Sleep abnormalities in Parkinson's disease (PD) are frequent, but it is unknown whether or not there is progressive loss of physiological sleep architecture or what the causes could be.
Retrospective review of medical records and polysomnographic data from 46 non-demented PD patients.
Sleep latency was correlated with disease duration (F1,44=4.87, P=0.03). Total sleep time (F1,44=8.54, P=0.005), deep sleep time (F1,44=4.06, P=0.05), REM sleep time (F1,44=9.15, P=0.004) and sleep efficiency (SE) (F1,44=10.20, P=0.003) were inversely correlated with disease duration. The same sleep parameters were independent from the degree of motor impairment, dosage of the dopaminergic medications, and age. Subjective sleep complaints could only partially predict abnormalities in polysomnographic (PSG) studies.
In PD nocturnal sleep 'destructuring' is linked to disease duration and evolves independently from other major disease parameters.

9 Reads
    • "Neurodegeneration and/or dysfunction in DA and multiple non-DA circuits [7] [183] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Parkinson disease is one of the neurodegenerative diseases that benefited the most from the use of non-human models. Consequently, significant advances have been made in the symptomatic treatments of the motor aspects of the disease. Unfortunately, this translational success has been tempered by the recognition of the debilitating aspect of multiple non-motor symptoms of the illness. Alterations of the sleep/wakefulness behavior experienced as insomnia, excessive daytime sleepiness, sleep/wake cycle fragmentation and REM sleep behavior disorder are among the non-motor symptoms that predate motor alterations and inevitably worsen over disease progression. The absence of adequate humanized animal models with the perfect phenocopy of these sleep alterations contribute undoubtedly to the lack of efficient therapies for these non-motor complications. In the context of developing efficient translational therapies, we provide an overview of the strengths and limitations of the various currently available models to replicate sleep alterations of Parkinson's disease. Our investigation reveals that although these models replicate dopaminergic deficiency and related parkinsonism, they rarely display a combination of sleep fragmentation and excessive daytime sleepiness and never REM sleep behavior disorder. In this light, we critically discuss the construct, face and predictive validities of both rodent and non-human primate animals to model the main sleep abnormalities experienced by patients with PD. We conclude by highlighting the need of integrating a network-based perspective in our modeling approach of such complex syndrome in order to celebrate valid translational models. Copyright © 2015 Elsevier Ltd. All rights reserved.
    Sleep Medicine Reviews 02/2015; DOI:10.1016/j.smrv.2015.02.005 · 8.51 Impact Factor
    • "Sleep disturbances in Parkinson's disease (PD) have been mentioned since the first descriptions by James Parkinson's Essay on the Shaking Palsy in 1817, but only recently they have become the subject of attention.[1] Sleep abnormalities in PD is possibly due to progressive sleep restructuring.[2] Sleep disorders seen in PD include insomnia, hypersomnia, and parasomnia. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: We studied the changes in Polysomnographic (PSG) profile in drug-naïve patients of Parkinson's disease (PD) who underwent evaluation with sleep overnight PSG. Materials and Methods: This prospective study included 30 with newly diagnosed levodopa-naïve patients with PD, fulfilling the UK-PD society brain bank clinical diagnostic criteria (M:F = 25:5; age: 57.2 ± 10.7 years). The disease severity scales and sleep related questionnaires were administered, and then patients were subjected to overnight PSG. Results: The mean duration of illness was 9.7 ± 9.5 months. The mean Hoehn and Yahr stage was 1.8 ± 0.4. The mean Unified Parkinson's Disease Rating Scale (UPDRS) motor score improved from 27.7 ± 9.2 to 17.5 ± 8.9 with sustained usage of levodopa. Nocturnal sleep as assessed by Pittsburgh Sleep Quality Index (PSQI) was impaired in 10 (33.3%) patients (mean PSQI score: 5.1 ± 3.1). Excessive day time somnolence was recorded in three patients with Epworth Sleepiness Scale (ESS) score ≥ 10 (mean ESS score: 4.0 ± 3.4). PSG analysis revealed that poor sleep efficiency of <85% was present in 86.7% of patients (mean: 68.3 ± 21.3%). The latencies to sleep onset (mean: 49.8 ± 67.0 minutes) and stage 2 sleep (36.5 ± 13.1%) were prolonged while slow wave sleep was shortened. Respiration during sleep was significantly impaired in which 43.3% had impaired apnoea hyperpnoea index (AHI) ≥5, mean AHI: 8.3 ± 12.1). Apnoeic episodes were predominantly obstructive (obstructive sleep apnea, OSA index = 2.2 ± 5.1). These patients had periodic leg movement (PLM) disorder (56.7% had PLM index of 5 or more, mean PLMI: 27.53 ± 4 9.05) that resulted in excessive daytime somnolence. Conclusions: To conclude, sleep macro-architecture is altered in frequently and variably in levodopa-naïve patients of PD and the alterations are possibly due to disease process per se.
    Annals of Indian Academy of Neurology 07/2014; 17(3):287-91. DOI:10.4103/0972-2327.138501 · 0.60 Impact Factor
  • Source
    • "1Sturrock and Rao (1985), 2Zhang et al. (2005), 3Naidoo et al. (2011), 4van der Zee et al. (1991), 5Carskadon et al. (1982), 6Foley et al. (2007), 7Magri et al. (1997), 8Touitou (1995), 9Whitehead et al. (2008), 10Huang et al. (2002), 11Davidson et al. (2008), 12Turek et al. (1995), 13Dykierek et al. (1998), 14Feinberg et al. (1967), 15Myers and Badia (1995), 16Brun and Englund (1981), 17Teipel et al. (2005), 18Vitiello et al. (1991), 19Satlin et al. (1995), 20Wu et al. (2007), 21Montplaisir et al. (1995), 22Tseng et al. (2010), 23Bonanni et al. (2005), 24Wu and Swaab (2007), 25Kang et al. (2009), 26Braak et al. (2004), 27Thannickal et al. (2007), 28Factor et al. (1990), 29Schenck et al. (1996), 30Postuma and Montplaisir (2009), 31Hartmann et al. (1997), 32Emser et al. (1988), 33Mouret (1975), 34Diederich et al. (2005), 35Willis and Turner (2007), 36Vonsattel et al. (1985), 37Kremer et al. (1991), 38Arnulf et al. (2008), 39Morton et al. (2005), 40Fish et al. (1991), 41Wiegand et al. (1991), 42Aziz et al. (2010), 43Maywood et al. (2010), 44Pallier et al. (2007), 45Sandyk (2006), 46Kimura et al. (1999), 47Atalaia et al. (2007), 48Lo Coco et al. (2011), 49Patacchioli et al. (2003), 50Barthlen and Lange (2000), 51Howard et al. (1989), 52David et al. (1997), 53Weishaupt et al. (2006). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Sleep/wake and circadian rest-activity rhythms become irregular with age. Typical outcomes include fragmented sleep during the night, advanced sleep phase syndrome and increased daytime sleepiness. These changes lead to a reduction in the quality of life due to cognitive impairments and emotional stress. More importantly, severely disrupted sleep and circadian rhythms have been associated with an increase in disease susceptibility. Additionally, many of the same brain areas affected by neurodegenerative diseases include the sleep and wake promoting systems. Any advances in our knowledge of these sleep/wake and circadian networks are necessary to target neural areas or connections for therapy. This review will discuss research that uses molecular, behavioral, genetic and anatomical methods to further our understanding of the interaction of these systems.
    Frontiers in Neurology 10/2011; 2:66. DOI:10.3389/fneur.2011.00066
Show more